Topera Medical Inc.
Division of Abbott Laboratories Inc.
Latest From Topera Medical Inc.
Abbott and St. Jude Medical are to lighten their cardiovascular portfolios – and hopefully facilitate the completion of Abbott's pending $25bn acquisition of St. Jude – by selling three product lines to Terumo. Two of the three product lines to be divested come as little surprise, but one product was acquired by Abbott only earlier this year.
The market for atrial fibrillation catheter ablation devices continues to grow even as the field wrestles with basic questions and as new study results may dampen enthusiasm for some technologies. Though strategics dominate this sector, innovators with new approaches to ablation and mapping hope to help resolve unknowns and take a piece of this vast and underpenetrated market.
Device companies raised 50% more in Q1 2016 than the previous quarter, reaching $1.8 billion and led by debt offerings; diagnostic imaging acquisitions, such as Toshiba Medical Systems, were abundant. Diagnostics financings double in Q1, mostly from venture funding, including strong showing from liquid biopsy companies.
Following two years of strong exits from biopharma and medtech investment, New Enterprise Associates raised over $3.1 billion for its 15th fund raising. The new pool of capital consists of $2.8 billion for a traditional venture fund – the fourth consecutive fund to top $2.5 billion – and a $350 million “Opportunity Fund” that will be co-invested with the new and prior fund in late-stage growth equity deals.
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Topera Inc.
- North America
- Parent & Subsidiaries
- Abbott Laboratories Inc.
- Senior Management
Arthur Taylor, Pres, COO & CFO
Ruchir Sehra, MD, CMO
Rick Green, VP, Sales & Mktg.
- Contact Info
Topera Medical Inc.
Phone: (650) 681-1740
1530 O’Brien Dr.
Menlo Park, CA 94025
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.